Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;14(5):1154-1172.
doi: 10.1007/s13346-023-01478-6. Epub 2023 Nov 25.

Progress of nanomaterials in the treatment of thrombus

Affiliations
Review

Progress of nanomaterials in the treatment of thrombus

Yetong Shen et al. Drug Deliv Transl Res. 2024 May.

Abstract

Thrombus has long been the major contributor of death and disability because it can cause adverse effects to varying degrees on the body, resulting in vascular blockage, embolism, heart valve deformation, widespread bleeding, etc. However, clinically, conventional thrombolytic drug treatments have hemorrhagic complication risks and easy to miss the best time of treatment window. Thus, it is an urgent need to investigate newly alternative treatment strategies that can reduce adverse effects and improve treatment effectiveness. Drugs based on nanomaterials act as a new biomedical strategy and promising tools, and have already been investigated for both diagnostic and therapeutic purposes in thrombus therapy. Recent studies have some encouraging progress. In the present review, we primarily concern with the latest developments in the areas of nanomedicines targeting thrombosis therapy. We present the thrombus' formation, characteristics, and biomarkers for diagnosis, overview recent emerging nanomedicine strategies for thrombus therapy, and focus on the future design directions, challenges, and prospects in the nanomedicine application in thrombus therapy.

Keywords: Drug delivery; Nanomedicine; Nanoparticles; Nanostrategy; Synergistic therapy; Targeted thrombolysis; Thrombolysis; Thrombus.

PubMed Disclaimer

Similar articles

References

    1. Zenych A, Fournier L, Chauvierre C. Nanomedicine progress in thrombolytic therapy. Biomaterials. 2020;258:120297.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
    1. Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20(4):248–62. - PubMed - DOI
    1. Correa-Paz C, da Silva-Candal A, Polo E, Parcq J, Vivien D, Maysinger D, et al. New approaches in nanomedicine for ischemic stroke. Pharmaceutics. 2021;13(5).
    1. Wang Y, Pisapati AV, Zhang XF, Cheng X. Recent developments in nanomaterial-based shear-sensitive drug delivery systems. Adv Healthc Mater. 2021;10(13):e2002196.

Substances

LinkOut - more resources